Form 4: Corcept Therapeutics Executive Hazel Hunt Reports Stock Option Grant

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, reports the acquisition of stock options in a recent SEC filing.

Summary

• On February 28, 2025, Hazel Hunt, the Chief Scientific Officer of Corcept Therapeutics, acquired stock options to purchase 140,000 shares of common stock.
• The exercise price of these options is $60.58 per share.
• The options vest ratably in equal monthly installments over a four-year period, contingent upon continued service.
• The options expire on February 28, 2035.
• Following the transaction, Ms. Hunt directly owns options for 140,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer can be seen as an incentive to align their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with company performance.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their key personnel.
• The vesting schedule of four years is also typical, aligning with industry norms for long-term performance incentives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Scientific Officer to drive company performance.
• Employees may see this as a sign of investment in leadership and future growth.

Key Dates